

	Month (%)	Quarter (%)	FYTD (%)	1 Year (%)	2 Years (% p.a.)	3 Years (% p.a.)	Since Inception [^] (% p.a.)	Since Inception Cumulative [^] (%)
Perennial Better Future Trust (Net)	-0.9	4.6	4.3	31.9	18.0	18.2	15.5	71.8
S&P/ASX Small Ordinaries Accumulation Index	0.9	3.7	4.4	31.0	13.1	13.5	9.5	40.7
Value Added	-1.8	0.9	-0.1	0.9	4.9	4.7	6.0	31.1

[^]Since inception: 1 February 2018. Past performance is not a reliable indicator of future performance.

Overview

The Better Future Trust was down 0.9% net of fees in October, underperforming the benchmark return by 1.8%.

The Trust has been running for more than three and a half years. It is a key goal of the Trust to demonstrate that there is no performance trade-off to invest for shaping a better future. Since inception in February 2018, the Trust has delivered a 15.5% p.a. return net of fees, outperforming the benchmark by 6.0% p.a.

Positive contributors this month included Janison Education (+18.1%), Imricor Medical Systems (+17.4%) and 3P Learning (+16.2%).

Negative contributors this month included Control Bionics (-27.8%), Pental (-19.6%) and Smartgroup (-15.6%).

Better Future Highlight

Last month, we established a position in 3P Learning ("3PL") in the portfolio. 3PL is best known for its Mathletics product that is used by schools in Australia and globally to encourage primary school students to develop their maths skills in a way that is more like play than traditional techniques.

3PL recently merged with Blake eLearning which owns the Reading Eggs product which takes a similar "play" approach to teaching children to read.

The company has been re-energised following the merger with a number of people who were involved in Mathletics when it was a start-up and who went on to develop Reading Eggs joining 3PL.

Historically, Mathletics' key focus has been on providing the product to schools, while the key focus of the Reading Eggs team was on direct-to-consumer markets.

Moving forward, the company is looking to revitalise the Mathletics program and focus the merged company's increased resources on both the school and direct-to-consumer markets globally for Reading Eggs and Mathletics. This is likely to be beneficial for both students globally and 3PL's prospects.

Perennial Better Future Trust

The aim of the Trust is to grow the value of your investment over the long term by investing in companies predominantly outside the S&P/ASX Top 50 Index that conduct business taking into account environmental, social and governance ("ESG") considerations and/or businesses that are making a positive contribution to creating a better future. The Trust seeks to provide a total return (after fees) that exceeds the S&P/ASX Small Ordinaries Accumulation Index measured on a rolling three-year basis.

Portfolio Manager

Damian Cottier

APIR Code

WPC5600AU

Distribution Frequency

Annually (if any)

Minimum Initial Investment

\$25,000


Trust Inception Date

1 February 2018

Fees

1.20% p.a. + Performance fee


Performance Since Inception



Value of A\$100,000 since inception (1 February 2018) of the Better Future Trust as at 31 October 2021.

Performance shown net of fees with distributions reinvested. Does not take into account any taxes payable by an investor. Past performance is not a reliable indication of future performance.

Portfolios Contribution to the UN Sustainable Development Goals



Total Contribution: 72.26%

(equal to 58.66% social impact contribution and 13.6% environmental impact contribution)

Source: Data provided by the Sustainable Platform 31 Aug 2021; based on company revenues

Trust Review

The Better Future Trust was down 0.9% net of fees in October, underperforming the benchmark return by 1.8%.

The Trust has been running for more than three and a half years. It is a key goal of the Trust to demonstrate that there is no performance trade-off to invest for shaping a better future. Since inception in February 2018, the Trust has delivered a 15.5% p.a. return net of fees, outperforming the benchmark by 6.0% p.a.

Positive contributors this month included Janison Education (+18.1%), Imricor Medical Systems (+17.4%) and 3P Learning (+16.2%).

Negative contributors this month included Control Bionics (-27.8%), Pental (-19.6%) and Smartgroup (-15.6%).

Janison Education provided a positive AGM trading update and announced a small "bolt-on" acquisition of the Quality Assessment Tasks ("QAT") business. The QAT business is an Australian market leader in the development of school assessments for Year 11 and 12 subjects. Janison will integrate the business including assessments, question bank and network of question developers and reviewers into Janison's existing business and exam platform.

Imricor Medical Systems announced that the company had signed the Semmelweis Heart and Vascular Centre in Budapest, Hungary as a new client. Cardiac catheter ablation procedures using Imricor's products are expected to commence this year. The leader of the program that will be using the products is Dr. Bela Merkely, who received the prestigious Szechenyi Prize this year, honouring the greatest scientists in Hungary alive today.

Smartgroup, which announced it had received a non-binding indicative proposal last month, announced that the potential acquirer of the business no longer intended to proceed with the offer at the initially indicated price. The board rejected a lower proposed price given the outlook for the business and reaffirmed that the company was trading in line with market expectations.

Control Bionics provided a slightly softer than expected quarterly update due to the ongoing COVID disruptions in both Australian and the US. In our view the company's products that assist people with conditions such as MMD and spinal injuries to communicate are well positioned once these headwinds abate.

During the month, we established a small position in Impedimed as part of a capital raising. The funds were raised to support growth after the company announced the results of a medical trial of the company's bioimpedance spectroscopy (BIS) product that was conducted in 1,200 patients across 10 trial sites in the US and Australia. The study demonstrated that early detection of cancer-related lymphoedema using the company's product resulted in a significantly lower rate of progression to chronic lymphoedema than patients using the existing standard of care. The use of the product will lead to better outcomes for breast cancer patients at risk of lymphoedema.

At month end, the portfolio held 50 stocks and cash of 8.3%.

At October end, the weighted average Perennial-derived Environmental, Social, Governance and Engagement ("ESGE") Score of the Trust was 7.2 which is 26% higher than the benchmark ESGE Score of 5.7.

Invest Online Now

Contact us



Level 27, 88 Phillip Street
Sydney NSW 2000



1300 730 032



invest@perennial.net.au



www.perennial.net.au

Signatory of:



Issued by: Perennial Partners Limited ABN 90 612 829 160 as a Corporate Authorised Representative (No. 1293138) of Perennial Value Management. The Investment Manager, Perennial Value Management Limited, ABN 22 090 879 904, AFSL: 247293. Responsible Entity: Perennial Investment Management Limited ABN 13 108 747 637, AFSL: 275101. This promotional statement is provided for information purposes only. Accordingly, reliance should not be placed on this promotional statement as the basis for making an investment, financial or other decision. This promotional statement does not take into account your investment objectives, particular needs or financial situation and is not intended to constitute advertising or advice of any kind and you should not construe the contents of promotional statement as legal, tax, investment or other advice. This promotional statement does not constitute an offer or inducement to engage in an investment activity nor does it form part of any offer documentation, offer or invitation to purchase, sell or subscribe for interests in any type of investment product or service. You should read and consider any relevant offer documentation applicable to any investment product or service and consider obtaining professional investment advice tailored to your specific circumstances before making any investment decision. While every effort has been made to ensure the information in this promotional statement is accurate; its accuracy, reliability or completeness is not guaranteed. Past performance is not a reliable indicator of future performance. Gross performance does not include any applicable management fees or expenses. Net performance is based on redemption price for the period and assumes that all distributions are reinvested. Fees indicated reflect the maximum applicable. Contractual arrangements, including any applicable management fee, may be negotiated with certain large investors. Investments in the Trusts must be accompanied by an application form. The current relevant product disclosure statements, additional information booklet, application forms and target market determination can be found on Perennial's website www.perennial.net.au. Use of the information on our website is governed by Australian law and is subject to the terms of use. No distribution of this material will be made in any jurisdiction where such distribution is not authorised or is unlawful.

ESG Activity

Our ESG activity during the month included:

- Kathmandu announced the appointment of Abby Foote as a director which is pleasing after our past engagement with the company on gender diversity. The company also recently appointed Brooke Farris as the CEO of the company's key Rip Curl business.
- We met with 3P Learning to discuss the company's approach to governance, gender diversity, initiatives to provide the company's products to disadvantaged students and ESG reporting post the Blake eLearning merger.
- We met with Opthea to discuss the company's plans on ESG reporting and remuneration structures for directors.
- We met with Control Bionics to discuss governance and remuneration structures, ESG reporting and gender diversity.
- We met with Bendigo Bank to discuss the company's carbon targets, lending practices and their general approach to ESG.
- We met with Integral Diagnostics to suggest improvements to the company's long term incentive structures to include an additional return on invested capital metric.

Top 5 Active Positions

Trust (%)	Index (%)
Janison Education	0.0
Calix	0.0
Immutep	0.0
Meridian Energy	0.0
Bendigo Bank	0.0

Better Future and ESG Team

Damian Cottier
Portfolio Manager

Emilie O'Neill
Co-Head of ESG &
Equities Analyst



CERTIFIED BY RIAA



The Perennial Better Future Trust has been certified by the Responsible Investment Association Australasia according to the strict operational and disclosure practices required under the Responsible Investment Certification Program. See www.responsiblereturns.com.au for details¹.

1. The Responsible Investment Certification Program does not constitute financial product advice. Neither the Certification Symbol nor RIAA recommends to any person that any financial product is a suitable investment or that returns are guaranteed. Appropriate professional advice should be sought prior to making an investment decision. RIAA does not hold an Australian Financial Services Licence.